Obesity Drugs in the Pipeline

As advancements in medical technology continue to flourish, there is no denying that the field of pharmacology is also making progress. Researchers are tirelessly working on creating a better future by developing newer generations of drugs that can offer more effective and safer options for patients worldwide. With promising pre-clinical and clinical trial results, it is apparent that we are approaching the age of second and third generation medications. The potential benefits of these drugs are enormous, as they can provide a much-needed alternative to those who have not seen successful results with previous medicine. Among the promising and ongoing developments in pharmaceuticals, our team is keeping a vigilant watch on these second and third generation drugs in the pipeline, as we eagerly await their release and the impact that it could have on the medical world.

GenericCompanyType of DrugMOAApprovedClinical TrialsReferences
(nonproprietary)
setmelanotideRhythm Pharmaceuticalsmelanocortin-4 receptor agonistmelanocortin-4 receptor, this drug is in development for rare genetic disorders associated with obesityNCT03013543
tesofensineNeuroSearch (Danish)serotonin-norepinephrine-dopamine receptor inhibitorinhibits the uptake of neurotrasnsmitters like dopamine, serotonin, and norepinephrine
bimagrumabNovartismononclonaltargets a receptor that blocks skeletal muscle growth,NCT03005288
tirzepatideEli Lillydual GINCT04184622 and GLP-1 receptor agonist that aims to control appetite and improve glycemic controlFDA-Late 2023?NCT04184622
retatrutideEli Lillytriple-hormone-recptor agonistNCT05929066
NCT05882045
NCT05929079
NCT05931367
NCT05936151
Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML; Retatrutide Phase 2 Obesity Trial Investigators. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. N Engl J Med. 2023 Aug 10;389(6):514-526. doi: 10.1056/NEJMoa2301972. Epub 2023 Jun 26. PMID: 37366315.